Skip to main content
SpringerLink
Log in

Infliximab not cost effective for ulcerative colitis in Poland

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Active Ulcerative Colitis Trial (ACT); Ulcerative Colitis Long-term Remission and Maintenance with Adalimumab (ULTRA)

  2. 2015 US dollars

Reference

  • Stawowczyk E, et al. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland. Pharmacotherapy : 23 Mar 2016. Available from: URL: http://doi.org/10.1002/phar.1742

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Infliximab not cost effective for ulcerative colitis in Poland. PharmacoEcon Outcomes News 750, 19 (2016). https://doi.org/10.1007/s40274-016-2942-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2942-3

Search

Navigation